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Abstract 
New vaccine formulations that include novel strains of Mycoplasma hyopneumoniae and innovative adjuvants 
designed to induce cellular immunity could improve vaccine efficacy against this pathogen. The aim of this experi‑
mental study was to assess the efficacy of three experimental bacterin formulations based on M. hyopneumoniae field 
strain F7.2C which were able to induce cellular immunity. The formulations included a cationic liposome formulation 
with the Mincle receptor ligand trehalose 6,6‑dibehenate (Lipo_DDA:TDB), a squalene‑in‑water emulsion with Toll‑like 
receptor (TLR) ligands targeting TLR1/2, TLR7/8 and TLR9 (SWE_TLR), and a poly(lactic‑co‑glycolic acid) micro‑particle 
formulation with the same TLR ligands (PLGA_TLR). Four groups of 12 M. hyopneumoniae‑free piglets were primo‑ (day 
(D) 0; 39 days of age) and booster vaccinated (D14) intramuscularly with either one of the three experimental bacterin 
formulations or PBS. The pigs were endotracheally inoculated with a highly and low virulent M. hyopneumoniae strain 
on D28 and D29, respectively, and euthanized on D56. The main efficacy parameters were: respiratory disease score 
(RDS; daily), macroscopic lung lesion score (D56) and log copies M. hyopneumoniae DNA determined with qPCR on 
bronchoalveolar lavage (BAL) fluid (D42, D56). All formulations were able to reduce clinical symptoms, lung lesions 
and the M. hyopneumoniae DNA load in the lung, with formulation SWE_TLR being the most effective  (RDSD28–D56 
−61.90%, macroscopic lung lesions −88.38%, M. hyopneumoniae DNA load in BAL fluid (D42) −67.28%). Further 
experiments raised under field conditions are needed to confirm these results and to assess the effect of the vaccines 
on performance parameters.
© The Author(s) 2019. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creat iveco mmons .org/licen ses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/
publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Introduction
Mycoplasma hyopneumoniae (M. hyopneumoniae) is the 
primary pathogen of enzootic pneumonia (EP) in pigs. 
This chronic respiratory disease is responsible for major 
economic losses in pig producing countries all over the 
world due to reduced performance and increased medi-
cation use [1, 2].
Together with biosecurity measurements, management 
practices and medication, commercial bacterin vaccines 
are used worldwide to control EP [1]. They are mostly 
constituted of inactivated whole cells of the J strain, a low 
virulent M. hyopneumoniae field strain isolated in the 
UK in the 1950s [3], and adjuvants such as aluminium 
hydroxide, carbopol, mineral oil or biodegradable oil [4]. 
Vaccination reduces clinical symptoms, lung lesions and 
performance losses [5, 6]. However, current commercial 
vaccines neither prevent colonisation of the pathogen, 
nor the development of clinical signs and lung lesions [7]. 
Also, their effect on disease transmission is only limited 
[8–10]. Moreover, the beneficial effects of vaccination are 
known to vary between herds [4], which may be partially 
due to pathogenic and antigenic differences between the 
strains circulating on the farms and the vaccine strain 
[11].
Open Access
*Correspondence:  Anneleen.Matthijs@ugent.be
1 Department of Reproduction, Obstetrics and Herd Health, 
Faculty of Veterinary Medicine, Ghent University, Salisburylaan 133, 
9820 Merelbeke, Belgium
Full list of author information is available at the end of the article
s
o
u
r
c
e
:
 
ht
tp
s:
//
do
i.
or
g/
10
.7
89
2/
bo
ri
s.
14
03
03
 
| 
do
wn
lo
ad
ed
: 
16
.3
.2
02
0
Page 2 of 14Matthijs et al. Vet Res           (2019) 50:91 
While serum antibodies are not correlated with pro-
tection against EP [12], the role of mucosal antibodies 
(immunoglobulin (Ig) A) is still unclear. According to 
Thacker et al. [13], mucosal IgA could prevent colonisa-
tion of the microorganism in the respiratory tract of the 
pig. Cell-mediated immune responses, more specifically 
T helper (Th) 1, Th17 and  CD8+ T cell responses, are 
considered to play a major role in protective immunity 
against M. hyopneumoniae infections [13–16]. T helper 
1 cells are considered to contribute to protection against 
Mycoplasma infections by activating macrophage killing 
[14], while Th17 cells protect the lung mucosa by elevat-
ing secretory IgA levels [17] and recruiting neutrophils 
for pathogen clearance [18].  CD8+ T cells, on the other 
hand, might dampen the excessive pro-inflammatory Th 
responses that induce lung lesions and clinical disease 
[19].
Research into novel vaccine formulations that may 
offer a better protection against M. hyopneumoniae is 
constantly ongoing. An overview of the different experi-
mental M. hyopneumoniae vaccines already showed that 
most of them are based on recombinant proteins of M. 
hyopneumoniae and were evaluated in mice [4]. Merely 
a few of them were tested in challenge experiments in 
pigs. Also, none of these formulations were able to offer 
total protection or similar protection as the commercially 
available vaccines, despite their often promising immu-
nizing properties [4, 20].
In a previous study [21], the safety and the immune 
responses of five innovative bacterin formulations were 
evaluated in pigs. All formulations were based on M. hyo-
pneumoniae strain F7.2C, a highly virulent field strain 
shown to be antigenically different from the J strain [22, 
23], and contained adjuvants specifically designed to pro-
mote cellular immunity. Three promising vaccine formu-
lations were identified based on their ability to induce 
potent M. hyopneumoniae-specific T cell responses. 
These included a micro-particle and an oil-in-water for-
mulation to deliver a cocktail of Toll-like receptor (TLR) 
1/2, TLR9 and TLR7/8 ligands, and a cationic liposomal 
formulation to deliver a Mincle ligand. The liposomal 
formulation was able to induce strong Th1 and  CD8+ 
T cell responses, while the oil-in-water formulation 
induced a strong Th1 response and a moderate  CD8+ T 
cell response. The micro-particle formulation had the 
unique ability of inducing a potent Th17 response. There-
fore, the aim of this study was to assess the protective 
efficacy of these three innovative bacterin formulations 
against experimental infection with two M. hyopneu-
moniae field strains. The main efficacy parameters were 
respiratory disease score (RDS), macroscopic lung lesion 
score and log copies M. hyopneumoniae DNA in bron-
choalveolar lavage (BAL) fluid. Additionally, microscopic 
lung lesions, M. hyopneumoniae-specific local and sys-
temic antibodies, M. hyopneumoniae-specific systemic T 
cell responses and cytokine responses in BAL fluid were 
assessed.
This study demonstrated the potential of innovative 
M. hyopneumoniae bacterin formulations and identified 
promising vaccine candidates for further exploration.
Materials and methods
Vaccines and adjuvants
Three adjuvant formulations were developed based 
on the association of particle-based delivery systems 
(liposomes, poly(lactic-co-glycolic acid) (PLGA) micro-
particles and a squalene-in-water emulsion (SWE)) with 
different immune stimulators. These included the Mincle 
agonist trehalose 6,6-dibehenate (Avanti, Alabaster, AL, 
USA) and a combination of TLR ligands: TLR1/2 ligand 
Pam3Cys-SK4 (PAM; EMC Microcollections, Tübingen, 
Germany), TLR9 ligand CpG oligodeoxynucleotides SL03 
(CpG; Eurofins Genomics, Les Ulis, France) and TLR7/8 
ligand resiquimod (Chemdea, Ridgewood, NJ, USA). The 
selection of the TLR ligands was based on their ability to 
activate porcine antigen presenting cells [24–26].
Trehalose 6,6-dibehenate (TDB) was combined 
with dimethyl dioctadecylammonium (DDA) bro-
mide with the thin lipid film method [27] and followed 
by extrusion to form the cationic liposome formulation 
Lipo_DDA:TDB. Cationic poly(lactic-co-glycolic acid) 
micro-particles (combined to ethylaminoethyl-dextran) 
were produced with the double emulsion (W/O/W) 
methods [28]. Pam3Cys-SK4 and resiquimod were 
encapsulated into the particles and CpG was subse-
quently adsorbed onto their surface for the PLGA_TLR 
formulation. The oil-in-water formulation SWE_TLR was 
obtained by mixing SWE (a squalene-based formulation 
developed and produced by the Vaccine Formulation 
Laboratory, and composed of 3.9% (w/v) squalene, 0.5% 
(w/v) Tween 80 and 0.5% (w/v) Span 85 [29]) with the 
immune stimulators PAM, CpG and resiquimod.
The vaccine strain M. hyopneumoniae F7.2C was grown 
in modified Friis medium [30] for 5 days at 35 ± 2 °C. The 
culture, containing 5 × 108 colour changing units (CCU)/
mL, was inactivated by incubation with 4 mM binary eth-
yleneimine (BEI) under agitation at 35 ± 2  °C for 24  h. 
Subsequently, the BEI was neutralised by incubating the 
inactivated culture with 4 mM sodium thiosulfate under 
agitation at 35 ± 2  °C for 24 h. Inactivated bacteria were 
pelleted at 15 000 g for 40 min at 4 °C and washed three 
times in 50  mL sterile phosphate buffered saline (PBS). 
The final pellet was resuspended in sterile PBS and mixed 
with the different adjuvants. The composition of each 
experimental vaccine is given in Table 1.
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Study animals and experimental design
The study was performed after approval by the Ethi-
cal Committee for Animal Experiments of the Faculty 
of Veterinary Medicine, Ghent University (approval 
number EC2017/120). Fifty-three M. hyopneumo-
niae-free Rattlerlow-Seghers piglets (RA-SE Genet-
ics NV, Ooigem, Belgium) were enrolled in the study. 
All animals originated from a herd that has been M. 
hyopneumoniae-free for many years based on repeated 
serological testing, nested PCR testing on tracheo-
bronchial swabs, and absence of clinical signs and 
pneumonia lesions at slaughter. The piglets arrived at 
the experimental facilities of the Faculty of Veterinary 
Medicine, Ghent University, Belgium at 32 days of age. 
They were housed in stables with absolute air filters for 
impending particles (HEPA U15) on both incoming 
and outgoing ventilation shafts and fed ad libitum with 
a non-antimicrobial-supplemented diet. On the day of 
arrival (D-7), the piglets were randomly allocated into 
three vaccination groups and a PBS-injected control 
group (PCG) of 12 piglets each. Five pigs were included 
as a non-challenge control group (NCG). After an accli-
matization period of 1 week, the pigs of the vaccination 
groups were prime-boost vaccinated intramuscularly 
(IM) at day (D) 0 and D14 of the study with 2  mL of 
experimental bacterin. The pigs of the PCG and NCG 
received 2 mL sterile PBS IM at both vaccination days. 
The pigs of the vaccinated groups and the PCG were 
experimentally infected by endotracheal inoculation 
of the highly virulent M. hyopneumoniae strain F7.2C 
(7  mL culture medium containing  107 CCU/mL) on 
D28 and the low virulent strain F1.12A (7  mL culture 
medium containing  107 CCU/mL) on D29 [31]. The 
pigs of the NCG were endotracheally inoculated with 
sterile culture medium on both challenge days. For the 
inoculations, the pigs were anesthetized by adminis-
tering 0.22  mL/kg body weight of a mixture of Zoletil 
 100® (Virbac, Louvain la Neuve, Belgium) and Xyl-M® 
2% (VMD, Arendonk, Belgium) IM. Four weeks after 
challenge infection (D56), all pigs were euthanized by 
exsanguination after deep anaesthesia with 0.3  mL/kg 
of the same mixture injected IM.
Clinical and performance parameters
The pigs were observed daily between 8 and 10 a.m. for 
at least 20 min from D-6 until D56 of the study. For each 
pig, remarkable clinical findings (loss of appetite, diar-
rhoea, dyspnoea, depression, lameness) were recorded 
and the severity of coughing was assessed by means of 
a RDS [32]. The scoring could range from 0 to 6 with 
0 = no coughing, 1 = mild coughing after an encouraged 
move, 2 = mild coughing in rest, 3 = moderate coughing 
after an encouraged move, 4 = moderate coughing in rest, 
5 severe coughing after an encouraged move, 6 = severe 
coughing in rest.
On the day of primo-vaccination (D0), challenge (D28) 
and euthanasia, the pigs were weighed, and the average 
daily gain (ADG; g/pig/day) was calculated from D0–28, 
D28–56 and D0–56 [33].
Macroscopic and microscopic lung lesions
At necropsy (D56), the lungs were removed and scored 
for macroscopic Mycoplasma-like lesions according 
to Hannan et al. [34]. The score could range from 0 (no 
lesions) to 35 (entire lung affected).
From each pig, samples from the left apical, cardiac and 
diaphragmatic lung lobe were collected for histopatho-
logical examination. If lesions were present, samples 
were taken from the border of the lesion. Each sample 
was scored for the degree of peribronchiolar and perivas-
cular lymphohistiocytic infiltration, as well as nodule 
formation, using light microscopy. A score system rang-
ing from 1 to 5 was used, with 1 = limited infiltration of 
macrophages and lymphocytes around bronchioles, with 
airways and alveolar spaces free of cellular exudates, 
2 = light to moderate infiltrates with mild diffuse cel-
lular exudates into airways, 3–4–5 = respectively mild, 
moderate and severe lesions characteristic of broncho-
interstitial pneumonia, centred around bronchioles but 
extending to the interstitium, with lymphofollicular 
infiltration and mixed inflammatory cell exudates [35]. 
Scores 1 and 2 are considered to be not related to M. hyo-
pneumoniae, while scores 3–5 are suggestive for an infec-
tion with M. hyopneumoniae.
Table 1 Composition of the experimental M. hyopneumoniae bacterins and their route of administration 
CCU: colour changing units, IM: intramuscular, PLGA: poly(lactic-co-glycolic acid), DDA: dimethyl dioctadecylammonium, TDB: trehalose 6,6′-dibehenate.
Vaccine formulation Dose 
(mL)
Delivery system Immune-stimulators (µg/
dose)
Antigen dose 
(CCU/dose)
Administration route 
(primo and booster)
Lipo_DDA:TDB 2 DDA liposomes TDB (500) 109 IM
PLGA_TLR PLGA micro‑particles (combined to 
ethylaminoethyl‑dextran)
Pam3Cys‑SK4/CpG ODN SL03/
resiquimod (80/80/80)
SWE_TLR Squalene‑in‑water emulsion
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The percentage of lung area occupied by air (% air) 
was assessed using an automated image analysis system 
(Leica Application Suite AF Lite (Diegem, Belgium) and 
ImageJ (Bethesda Softworks, Rockville, MD, USA) [31]).
Quantitative PCR for M. hyopneumoniae DNA and routine 
bacteriological culture on bronchoalveolar lavage fluid
Two weeks after challenge infection (D42), bronchoal-
veolar lavage fluid was collected from each pig by insert-
ing a catheter  (Portex® Dog Catheter with Female Luer 
Mount, Smiths Medical International Ltd., Kent, UK) in 
the trachea and flushing the lungs with 20 mL sterile PBS 
[31]. At necropsy (D56), BAL fluid was collected from 
the right lung by flushing the head bronchus with 20 mL 
sterile PBS as previously described [36]. Deoxyribonu-
cleic acid was extracted from the BAL fluid using a com-
mercial kit  (DNeasy® Blood & Tissue kit, Qiagen, Venlo, 
The Netherlands) and a quantitative PCR (qPCR) was 
performed according to Marois et al. [37] to measure the 
number of M. hyopneumoniae organisms. The threshold 
values were converted to the number of organisms using 
a tenfold dilution series of M. hyopneumoniae F7.2C 
DNA. Values below the highest dilution (1.50 × 101/mL; 
1.18 log copies/mL) were considered as negative.
From each pig, 10 µL of BAL fluid collected at D56 
was inoculated on a Columbia agar supplemented with 
5% sheep blood (Oxoid Limited, Hampshire, UK) with 
a Staphylococcus pseudintermedius streak [38]. The agar 
plates were incubated in a 5%  CO2-enriched atmosphere 
at 35 ± 2 °C for 48 h to detect the presence of other res-
piratory bacteria.
M. hyopneumoniae-specific antibody responses
Before primo-vaccination (D0), on the day of booster 
vaccination (D14), at challenge (D28), 2 weeks after chal-
lenge (D42) and at euthanasia (D56), serum samples were 
collected and the number of M. hyopneumoniae seropos-
itive animals was determined with a commercial blocking 
ELISA (IDEIA™ Mycoplasma hyopneumoniae EIA kit, 
Oxoid Limited, Hampshire, UK) according to the manu-
facturer‘s instructions. Samples with optical density (OD) 
lower than 50% of the average OD of the buffer control 
were considered positive. Samples with OD-values equal 
or bigger than 50% of the average OD of the buffer con-
trol were considered negative.
Mycoplasma hyopneumoniae-specific IgG and IgA 
isotypes were measured in serum (diluted 1:200 and 
1:100, respectively) with an in-house indirect ELISA 
using Tween 20-extracted M. hyopneumoniae antigens 
according to Matthijs et al. [21]. All samples were tested 
in duplicate. To relatively quantify the antibody levels, a 
standard curve was made using twofold serial dilutions 
of a positive reference serum corresponding to defined 
arbitrary units (1:800 and 1:200 dilution defined as 1 
unit for IgG and IgA, respectively). Optical density val-
ues of the samples were interpolated from the standard 
curve using non-linear regression with least square fits in 
Graphpad Prism 8.0 (GraphPad Software Inc., San Diego, 
CA, USA).
Mycoplasma hyopneumoniae-specific IgA antibodies 
in BAL fluid collected 2  weeks after challenge infection 
(D42) and at euthanasia (D56) were measured with an in-
house indirect ELISA as previously described [21]. The 
BAL fluid was tested undiluted and in duplicate. Anti-
body levels were also relatively quantified as described 
above using a standard curve made with positive BAL 
fluid (1:32 dilution defined as 1 unit). Animals with val-
ues higher than 0 arbitrary units were considered as posi-
tive, while animals with values equal to 0 arbitrary units 
were classified as negative.
T cell assays
Shortly before challenge infection (D28) and at eutha-
nasia (D56), blood samples were collected to assess M. 
hyopneumoniae-specific T cell responses according 
to Matthijs et  al. [21]. Peripheral blood mononuclear 
cells (PBMCs) were isolated and restimulated in  vitro 
overnight (18 h) with M. hyopneumoniae F7.2C bacte-
rin. For the last 4  h, Brefeldin A was added to inhibit 
cytokine release and allow intracellular detection of 
cytokines. Subsequently, cells were harvested and the 
percentage of cytokine-producing T cells was meas-
ured by flow cytometry (FCM) using a 5-step 6-col-
our staining protocol. Briefly, following incubation 
with the LIVE/DEAD™ Fixable Aqua Dead Cell Stain 
Kit (Invitrogen™, ThermoFisher Scientific, Waltham, 
MA, USA), cells were incubated with anti-CD4 (clone 
74-12-4, Southern Biotech, Birmingham, AL, USA) 
and anti-CD8β (clone PG164A, WSU, Pullman, WA, 
USA) antibodies and then with their corresponding 
secondary antibodies anti-mouse IgG2b AlexaFluor 
488 (Molecular Probes, Eugene, OR, USA) and anti-
mouse IgG2a PE-Cy7 (Abcam, Cambridge, UK). After 
fixation and permeabilization of the cells with the BD 
Cytofix/Cytoperm™ Fixation/Permeabilization Solu-
tion kit (Becton–Dickinson, Franklin Lakes, NJ, USA), 
intracellular cytokines were stained with directly cou-
pled anti-human TNF-α AlexaFluor 647 (clone MAb11, 
BioLegend, San Diego, CA, USA), anti-pig IFN-γ 
PerCP-Cy5.5 (clone P2G10, Becton–Dickinson) and 
anti-human IL-17A PE (clone SCPL1362, Becton–Dick-
inson). All samples were acquired on a CytoFLEX flow 
cytometer (Beckman Coulter, Brea, CA, USA) and the 
analysis performed with the FlowJo™ software (Tree 
Star Inc., Ashland, OR, USA). For each animal, samples 
were restimulated in triplicate cultures and analysed 
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separately. To define whether an animal had M. hyo-
pneumoniae-specific circulating cells, a threshold value 
was calculated as the mean % of cytokine-producing 
 cellsall control animals + 3*SDall control animals for D28, and as 
the mean % of cytokine-producing  cellsNCG + 3*SDNCG 
for D56. Animals with values above the threshold were 
identified as positive, while animals with values equal 
to or below the threshold were classified as negative.
Cytokines in BAL fluid
The BAL fluid collected at D42 and D56 was tested undi-
luted for the presence of IL-1β (Porcine IL-1 beta/IL-1F2 
 DuoSet® ELISA, R&D Systems, Minneapolis, MN, USA), 
IL-6 (Porcine IL-6  DuoSet® ELISA, R&D Systems, Min-
neapolis, MN, USA), IFN-γ (Swine IFN-γ Antibody Pair, 
Invitrogen™, ThermoFisher Scientific) and TNF-α (Swine 
TNF-α CytoSet™, Invitrogen™, ThermoFisher Scientific) 
using a sandwich ELISA according to the manufacturer‘s 
instructions. The OD-values were converted to cytokine 
levels by means of a standard curve.
Statistical analyses
The RDS data was averaged for the periods D-6 until 
D56, D-6 until D27 and D28 until D56, and analysed 
using a repeated measures ANOVA. Pairwise compari-
sons between groups were obtained with Scheffé’s post 
hoc test. The T cell data was analysed using a one-way 
ANOVA with Tukey–Kramer’s post hoc test for pairwise 
comparisons. The parameters ADG, macroscopic lung 
lesions, microscopic lung lesions, % air, log copies M. 
hyopneumoniae DNA in BAL fluid, M. hyopneumoniae-
specific IgG, M. hyopneumoniae-specific IgA (serum, 
BAL fluid), IL-1, IL-6, IFN-γ and TNF-α were not nor-
mally distributed according to the Shapiro–Wilk’s test, 
and were analysed using a Kruskal–Wallis ANOVA fol-
lowed by Dunn’s post hoc test. Adjusted P values were 
computed to account for multiple comparisons, except 
for Scheffé’s post hoc test, which is already quite con-
servative [39]. The NCG was not included in the sta-
tistical analyses as this group only served as a sentinel 
group. Statistical analyses of efficacy parameters were 
conducted in SPSS 24 for Windows (IBM, Armonk, NY, 
USA). Immune response parameters were analysed using 
GraphPad Prism 8.0 (GraphPad Software Inc., San Diego, 
CA, USA). Statistical results were considered significant 
when P ≤ 0.05.
Results
Clinical and performance parameters
General health, severity of coughing (daily RDS) and 
ADG of each piglet were closely monitored during the 
entire study. One piglet from the PCG died during anaes-
thesia on D28. This piglet was excluded from the RDS 
and ADG analyses. On D42, one piglet from the Lipo_
DDA:TDB group showed severe abdominal breathing 
after blood sampling. Therefore, BAL fluid was not col-
lected from that animal on D42.
None of the non-challenge control animals coughed, 
except for one pig on D44 (score 2, mild coughing in 
rest). An increase in the mean RDS was first observed 
in group Lipo_DDA:TDB from 6 to 8  days post chal-
lenge (DPC) onwards, followed by groups SWE_TLR, 
PCG and PLGA_TLR, respectively from 8, 9 and 10 
DPC onwards. After several days, coughing decreased in 
the vaccinated groups, while it continued at a high level 
in the PCG until the end of the study (Figure  1). After 
challenge infection (D28–56), formulation SWE_TLR 
induced the highest reduction in mean RDS compared to 
the PCG (61.90%), followed by formulations PLGA_TLR 
and Lipo_DDA:TDB (50.34% and 38.78%, respectively). 
However, the reduction of coughing was only statistically 
significant for group SWE_TLR (P ≤ 0.05; Table 2). 
For each group, the mean ADG from D0–56, D0–28 
and D28–56 is shown in Table 2. After challenge infection 
(D28–56), ADG from group SWE_TLR was significantly 
higher compared to the other vaccinated groups (P ≤ 0.05).
Macroscopic and microscopic lung lesions
At euthanasia (D56), lungs were collected and scored 
for macroscopic and microscopic lung lesions. The per-
centage of lung area occupied by air was measured using 
image analysis. The results are presented in Table 2. Mac-
roscopic lung lesions were observed in all animals from 
the PCG, and in 7/12 animals from each of the vaccinated 
groups. In the NCG, none of the animals either had mac-
roscopic lung lesions, nor microscopic lung lesion scores 
higher than 2. All vaccinated groups had a significantly 
lower macroscopic lesion score compared to the PCG 
(P ≤ 0.05). Formulation SWE_TLR induced the high-
est reduction in macroscopic lung lesions compared to 
the PCG (88.38%), while formulations PLGA_TLR and 
Lipo_DDA:TDB reduced macroscopic lung lesions with 
81.11% and 69.88%, respectively. All three formulations 
significantly reduced microscopic lung lesions (P ≤ 0.05), 
and the highest reduction was again observed in group 
SWE_TLR. Groups Lipo_DDA:TDB and SWE_TLR had 
a significantly higher percentage of lung area occupied by 
air compared to the PCG (P ≤ 0.05).
Quantitative PCR for M. hyopneumoniae DNA and routine 
bacteriological culture on bronchoalveolar lavage fluid
The number of animals positive for M. hyopneu-
moniae DNA in BAL fluid and mean log copies M. 
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hyopneumoniae DNA in BAL fluid are shown for each 
group in Table  2. Two weeks after challenge infection 
(D42), significantly lower numbers of M. hyopneumoniae 
organisms were detected in BAL fluid from groups 
PLGA_TLR and SWE_TLR compared to the PCG 
(P ≤ 0.05). The reduction in log copies M. hyopneumoniae 
0 14 28 42 56
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m
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n
R
DS
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PCG
Lipo_DDA:TDB
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Figure 1 Mean respiratory disease score for each group during the entire study. NCG: non‑challenge control group (PBS‑injected, 
non‑challenge infected), PCG: PBS‑injected control group (PBS‑injected, challenge infected), RDS: respiratory disease score.
Table 2 Overview of the efficacy data 
Pigs were prime-boost vaccinated on D0 and D14 with three different experimental M. hyopneumoniae bacterins (Lipo_DDA:TDB, PLGA_TLR, SWE_TLR), challenge 
infected on D28–29 and euthanized on D56. For the parameters ADG, macroscopic lung lesion score, microscopic lung lesion score, % air and number of M. 
hyopneumoniae organisms in BAL fluid, a Kruskal–Wallis ANOVA was performed to determine statistical differences between the groups on each time point. For the 
parameter RDS, a repeated measurements ANOVA with Scheffé’s post hoc test was performed. The NCG was not included in the statistical analyses. Groups that have 
no superscript in common are significantly different from each other (P ≤ 0.05). All results are expressed as mean ± SD, unless otherwise stated.
NCG: non-challenge control group (non-vaccinated, non-challenge infected), PCG: PBS-injected control group (non-vaccinated, challenge infected), RDS: respiratory 
disease score, ADG: average daily gain, BAL: bronchoalveolar lavage.
Parameter Study day NCG PCG Lipo_DDA:TDB PLGA_TLR SWE_TLR P value
RDS −6 until 56 0.01 ± 0.01 0.68 ± 0.32b 0.42 ± 0.33ab 0.33 ± 0.35ab 0.26 ± 0.15a 0.011
−6 until 27 0.00 ± 0.00 0.00 ± 0.00a 0.00 ± 0.00a 0.00 ± 0.00a 0.00 ± 0.01a 0.415
28 until 56 0.01 ± 0.03 1.47 ± 0.69b 0.90 ± 0.73ab 0.73 ± 0.77ab 0.56 ± 0.33a 0.011
ADG in g/pig/d 0 until 56 691 ± 69 655 ± 109a 610 ± 90a 628 ± 97a 688 ± 49a 0.065
0 until 28 620 ± 47 592 ± 104a 560 ± 104a 586 ± 106a 581 ± 70a 0.526
28 until 56 762 ± 98 739 ± 141ab 660 ± 96a 669 ± 127a 795 ± 69b 0.004
Number of animals with macroscopic lung 
lesions (% positive animals)
56 0/5 (0.00) 11/11 (100.00) 7/12 (58.33) 7/12 (58.33) 7/12 (58.33) –
Macroscopic lung lesion score 56 0.00 ± 0.00 7.57 ± 5.18b 2.28 ± 3.55a 1.43 ± 2.31a 0.88 ± 1.01a 0.002
Microscopic lung lesion score 56 1.13 ± 0.18 3.73 ± 0.94b 2.11 ± 0.89a 2.22 ± 0.87a 1.78 ± 0.57a < 0.001
Percentage of lung area occupied by air 56 39.11 ± 6.26 23.38 ± 6.43b 37.57 ± 5.99a 34.82 ± 4.28ab 42.15 ± 7.98a < 0.001
Number of animals positive for M. hyopneumo-
niae in BAL fluid (% positive animals)
42 0/5 11/11 (100.00) 9/11 (81.82) 9/12 (75.00) 6/12 (50.00) –
56 0/5 8/11 (72.73) 5/12 (41.67) 6/12 (50.00) 4/12 (33.33) –
Log copies M. hyopneumoniae DNA/mL BAL fluid 42 0.00 ± 0.00 3.82 ± 0.71b 2.50 ± 1.18ab 2.20 ± 1.38a 1.25 ± 1.28a < 0.001
56 0.00 ± 0.00 1.74 ± 0.94a 1.24 ± 1.34a 1.76 ± 1.68a 0.63 ± 0.74a 0.082
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DNA was 42.41% and 67.28%, respectively. Formulation 
Lipo_DDA:TDB reduced the number of M. hyopneu-
moniae organisms in BAL fluid with 34.55% compared 
to the PCG, but this reduction was not statistically sig-
nificant (P > 0.05). At euthanasia (D56), all groups had a 
lower number of M. hyopneumoniae DNA in BAL fluid 
compared to D42 and no significant differences were 
observed between the groups (P > 0.05).
No other respiratory bacteria were detected after inoc-
ulating the BAL samples on Columbia blood agar plates.
M. hyopneumoniae-specific antibody responses
According to the commercial blocking ELISA (Addi-
tional file  1), all animals from group Lipo_DDA:TDB 
were positive for M. hyopneumoniae-specific antibod-
ies in serum 2 weeks after booster vaccination (D28). In 
groups PLGA_TLR and SWE_TLR, 5/12 and 11/12 pigs 
seroconverted, respectively. Two weeks after challenge 
infection (D42), all pigs from the vaccinated groups were 
seropositive, together with 7/11 pigs from the PCG. At 
euthanasia (D56), all pigs from the vaccinated groups and 
PCG were seropositive. The pigs form the NCG remained 
serologically negative for M. hyopneumoniae during the 
entire study.
Mycoplasma hyopneumoniae-specific IgG and IgA lev-
els in serum and M. hyopneumoniae-specific IgA levels 
in BAL fluid were quantified using an in-house indirect 
ELISA with positive reference serum or BAL fluid as a 
standard (Figures  2A–C). Two weeks after booster vac-
cination (D28), formulations Lipo_DDA:TDB and SWE_
TLR induced a significant M. hyopneumoniae-specific 
IgG response (P ≤ 0.05). Two weeks after challenge infec-
tion (D42) and at euthanasia (D56), all vaccinated groups 
had higher M. hyopneumoniae-specific IgG levels com-
pared to the PCG. This was statistically significant for all 
vaccinated groups (P ≤ 0.05) except group PLGA_TLR on 
D42 (Figure 2A).
Two weeks after primo-vaccination (D14) and 2 weeks 
after booster vaccination (D28), none of the vaccine 
formulations induced a significant M. hyopneumoniae-
specific IgA response in serum (P > 0.05). Nevertheless, 
2  weeks after challenge infection (D42), group Lipo_
DDA:TDB showed a significantly higher M. hyopneu-
moniae-specific IgA response compared to the PCG and 
group PLGA_TLR (P ≤ 0.05). Also, at euthanasia (D56), 
group Lipo_DDA:TDB had a significantly higher level of 
M. hyopneumoniae-specific IgA in serum compared to 
the PCG (P ≤ 0.05; Figure 2B).
According to the in-house IgA ELISA on BAL fluid, 
respectively 9/11, 6/12 and 5/12 animals from groups 
Lipo_DDA:TDB, PLGA_TLR and SWE_TLR had M. 
hyopneumoniae-specific IgA antibodies in BAL fluid col-
lected 2 weeks after challenge (D42). At euthanasia (D56), 
all animals from the vaccinated groups and the PCG 
were positive for M. hyopneumoniae-specific IgA. No 
IgA antibodies were detected in BAL fluid from the non-
challenge control animals on both sampling days (Addi-
tional file 1). Two weeks after challenge infection (D42), 
group Lipo_DDA:TDB showed a significantly higher M. 
hyopneumoniae-specific IgA response in BAL fluid com-
pared to the PCG (P ≤ 0.05). At euthanasia (D56), groups 
Lipo_DDA:TDB and SWE_TLR had significantly higher 
M. hyopneumoniae-specific IgA levels in BAL fluid com-
pared to the PCG, and group Lipo_DDA:TDB was also 
significantly higher than group PLGA_TLR (P ≤ 0.05; 
Figure 2C).
T cell assays
The results of the M. hyopneumoniae-specific T cell 
responses detected in the blood 2  weeks after booster 
vaccination (D28) are presented in Figures 3A–C. Group 
SWE_TLR had a significantly higher percentage of TNF-
producing  CD4+ (Th1) cells compared to the PCG and 
group PLGA_TLR (P ≤ 0.05). However, in this group 
only five animals were above the threshold. In the Lipo_
DDA:TDB group four animals and in group PLGA_TLR 
one animal were above the cut-off value (Figure  3A). 
For the  CD4+ IL-17A+ (Th17) cells, one pig from group 
Lipo_DDA:TDB and two pigs from group SWE_TLR 
were above the cut-off (Figure 3B). Two pigs from group 
Lipo_DDA:TDB, 1 pig from group PLGA_TLR and three 
pigs from group SWE_TLR showed circulating  CD8+ 
 TNF+IFN-γ+ T cells at the time of sampling. The per-
centage  CD8+  TNF+IFN-γ+ T cells in group SWE_TLR 
was significantly higher compared to the PLGA_TLR 
group (P ≤ 0.05; Figure 3C).
Four weeks after challenge (D56), group PLGA_TLR 
had a significantly higher percentage  CD4+  TNF+IFN-γ+ 
(Th1) cells compared to the PCG and the other two vac-
cinated groups (P ≤ 0.05), although merely five animals 
appeared to have such cells in the blood (Figure 3D). In 
the blood of one pig from the PCG and 1 pig of the Lipo_
DDA:TDB group  CD4+ IL-17A+ T cells were detected 
(Figure  3E). Only in the PLGA_TLR group one animal 
had  CD8+  TNF+IFN-γ+ T cells above the defined thresh-
old (Figure 3F).
Cytokines in BAL fluid
The concentrations of IL-1β, IL-6, IFN-γ and TNF-α in 
BAL fluid collected on D42 and D56 are presented for 
each group in Figures 4A–D. Two weeks after challenge 
infection (D42), the IL-1β concentration in BAL fluid was 
significantly higher in group Lipo_DDA:TDB compared 
to the PCG and group SWE_TLR (P ≤ 0.05). At eutha-
nasia (D56), group PLGA_TLR had a significantly lower 
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Figure 2 Antibody levels following vaccination and challenge infection. Pigs were prime‑boost vaccinated on D0 and D14 with three 
different experimental M. hyopneumoniae bacterins (Lipo_DDA:TDB, PLGA_TLR, SWE_TLR), challenge infected on D28–29 and euthanized on D56. 
M. hyopneumoniae‑specific IgG (A) and IgA (B) antibodies in serum and M. hyopneumoniae‑specific IgA in BAL fluid (C) were determined by indirect 
ELISA. Individual animals are shown. For each time point, significance was calculated using a Kruskal–Wallis ANOVA. The NCG was not included 
in the statistical analyses. Groups that have no superscript in common are significantly different from each other (P ≤ 0.05). NCG, non‑challenge 
control group (PBS‑injected, non‑challenge infected); PCG, PBS‑injected control group (PBS‑injected, challenge infected).
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IL-1β concentration compared to the PCG (P ≤ 0.05; 
Figure 4A).
Only in BAL fluid from group Lipo_DDA:TDB a sig-
nificant level of IFN-γ was detected on D42 (P ≤ 0.05). 
At euthanasia (D56), group SWE-TLR had a significantly 
higher IFN-γ concentration compared to group PLGA_
TLR (P ≤ 0.05; Figure 4C).
Regarding IL-6 and TNF-α, no statistically significant 
differences were observed between the groups on both 
time points (P > 0.05; Figures 4B and D).
Discussion
The present study assessed the protective efficacy of 
three innovative M. hyopneumoniae bacterin formula-
tions in a porcine experimental challenge model. The pigs 
were challenge infected with two M. hyopneumoniae field 
strains according to Michiels et  al. [31]. These included 
strain F7.2C (the vaccine strain) and strain F1.12A, which 
were shown to differ from each other on a genomic [40], 
proteomic [23] and pathogenic [22] level. Challenge 
infection with two genetically different field strains might 
improve extrapolation to the field situation compared to 
experimental infection with only one strain, as the study 
from Michiels et  al. demonstrated that most pigs were 
simultaneously infected with two or more genetically dif-
ferent M. hyopneumoniae strains under field conditions 
[41]. All animals from the PCG (PBS-injected, challenge 
infected) developed lung lesions, were positive for M. 
hyopneumoniae in BAL fluid and seroconverted, indicat-
ing that the challenge infection was successful. The values 
for the RDS and lung lesion scores in the PCG were com-
parable with those found in previous experimental stud-
ies using the same challenge model [31, 42].
A B C
D E F
Figure 3 M. hyopneumoniae-specific T cell responses following vaccination and challenge infection. Pigs were prime‑boost vaccinated on 
D0 and D14 with three different experimental M. hyopneumoniae bacterins (Lipo_DDA:TDB, PLGA_TLR, SWE_TLR), challenge infected on D28–29 
and euthanized on D56. M. hyopneumoniae‑specific T cells were determined by in vitro restimulation of PBMC followed by intracellular cytokine 
staining and multicolour flow cytometry. Following doublet exclusion, live cells were gated and the percentage of  TNF+  CD4+, IFNγ+TNF+ double 
positive  CD4+ and CD8β+ T cells, and IL‑17A+  CD4+ T cells was determined. The mean values obtained from triplicate cultures for individual 
animals are shown. Positive animals are marked in red (defined as being above the mean + 3*SD of all control animals on D28 and being above the 
mean + 3*SD of the NCG on D56). The horizontal line in each group represents the group mean. For each time point, significance between groups 
was calculated using one‑way ANOVA followed by Tukey–Kramer’s test. The NCG was not included in the statistical analyses. Groups that have 
no superscript in common are significantly different from each other (P ≤ 0.05). NCG, non‑challenge control group (PBS‑injected, non‑challenge 
infected); PCG, PBS‑injected control group (PBS‑injected, challenge infected); PBMC, peripheral blood mononuclear cells.
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According to the in-house serum ELISAs, some ani-
mals appeared to have M. hyopneumoniae-specific anti-
bodies before vaccination and/or challenge infection 
(animals with values higher than 0 arbitrary units; Fig-
ure 2). These animals most likely tested false positive due 
to non-specific binding, since the study animals were 
obtained from a M. hyopneumoniae-free farm. Moreo-
ver, the particular pigs tested negative in the commercial 
blocking ELISA on those time points. While the com-
mercial kit uses a highly specific monoclonal antibody 
against a conserved epitope of the M. hyopneumoniae 
74  kDa protein, our in-house indirect ELISA is based 
on Tween 20-extracted proteins of M. hyopneumoniae. 
Such crude antigen preparations more easily allow cross-
reactions with antibodies against the closely related M. 
flocculare, a commonly occurring commensal in the res-
piratory tract of pigs [43]. However, an additional M. floc-
culare ELISA to confirm the presence of such antibodies 
was not performed. In consequence, it remains uncertain 
whether all obtained in-house serum ELISA results are 
purely due to a M. hyopneumoniae response.
All three vaccine formulations were able to reduce clin-
ical signs, macroscopic lung lesions and histopathologi-
cal lung lesions, with formulation SWE_TLR being the 
most effective (RDS −61.9%, macroscopic lung lesions 
−88.4%, log copies M. hyopneumoniae DNA in BAL fluid 
−67.3%). The improvements obtained with formulation 
SWE_TLR seemed similar to or sometimes even better 
(adding up to 40% and 58% to the reduction of macro-
scopic lung lesions and log copies M. hyopneumoniae 
A B
C D
Figure 4 Cytokine concentrations (pg/mL) in bronchoalveolar lavage fluid. Pigs were prime‑boost vaccinated on D0 and D14 with three 
different experimental M. hyopneumoniae bacterins (Lipo_DDA:TDB, PLGA_TLR, SWE_TLR), challenge infected on D28–29 and euthanized on D56. 
IL‑1β (A), IL‑6 (B), IFN‑γ (C) and TNF‑α (D) concentrations in BAL fluid were measured using commercial sandwich ELISAs. For each time point, 
significance was calculated using a Kruskal–Wallis ANOVA. The NCG was not included in the statistical analyses. Groups that have no superscript 
in common are significantly different from each other (P ≤ 0.05). NCG, non‑challenge control group (PBS‑injected, non‑challenge infected), PCG, 
PBS‑injected control group (PBS‑injected, challenge infected), BAL, bronchoalveolar lavage.
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DNA, respectively) than the results obtained with com-
mercial M. hyopneumoniae bacterins under experimental 
conditions [11, 31, 44, 45]. However, due to differences 
in the experimental settings (i.e. age of vaccination, chal-
lenge strains, one-shot vs. two-shot vaccination), com-
parisons with other trials remain speculative. In order to 
properly compare the protective efficacy of the experi-
mental vaccines with the protection levels induced by 
commercial vaccines, a commercial two-shot vaccine 
should have been included in the experimental design. 
Interestingly, the protective efficacy of the highly viru-
lent F7.2C strain formulated as a bacterin in combina-
tion with an aqueous adjuvant was assessed in a previous 
study [11]. However, in that study, the experimental vac-
cine formulation did not offer significant protection 
against experimental infection. This might be explained 
by the use of a less potent adjuvant and/or the lower anti-
gen load (7.7 log10 CCU/mL) of the vaccine. Next to that, 
it should be mentioned that the vaccination was partially 
homologous to the challenge infection in this study, as 
strain F7.2C was used to construct the vaccines and was 
also one of the two challenge strains. One might suggest 
that this could result in better protection compared to 
challenge with strains different from the vaccine. Nev-
ertheless, Villarreal et  al. showed that vaccination with 
a bacterin homologous to the strain used for challenge 
infection did not result in an increased protection when 
compared to bacterins containing genetically heterolo-
gous strains [11].
Two weeks after challenge infection, groups SWE_TLR 
and PLGA_TLR had significantly lower numbers of M. 
hyopneumoniae organisms in BAL fluid compared to the 
PCG, indicating a lower shedding of M. hyopneumoniae 
in vaccinated pigs. However, like the current commercial 
vaccines, the experimental vaccine formulations from 
this study could not prevent colonization of the pathogen 
in the respiratory tract of the pigs.
Group SWE_TLR was the only group that had a higher 
ADG from the day of challenge until euthanasia. How-
ever, these findings were not statistically significant, most 
likely due to the small number of animals included in the 
study, the high SD of this parameter and the rather short 
study period [11, 31]. Further research including more 
animals and raised under field conditions is needed to 
obtain more reliable data on the impact of these experi-
mental vaccines on performance parameters such as 
ADG and feed conversion ratio (FCR).
In accordance with the results from a previous study 
[21], formulation Lipo_DDA:TDB was the most potent 
in inducing a serological IgG response. However, the 
reduction in lung lesions was the lowest in group Lipo_
DDA:TDB, confirming once more that systemic anti-
bodies do not correlate with protection against EP [12]. 
Mucosal IgA is considered important to control M. 
hyopneumoniae infection, as adherence of the bacte-
ria to the cilia of respiratory epithelium is the first step 
in the pathogenesis [13]. In the study from Matthijs 
et  al. [21], only one animal from group SWE_TLR had 
M. hyopneumoniae-specific IgA antibodies in BAL fluid 
2  weeks after booster vaccination. In the present study, 
groups Lipo_DDA:TDB and SWE_TLR had significantly 
more M. hyopneumoniae-specific IgA in BAL fluid col-
lected 4  weeks after challenge compared to the non-
vaccinated animals. Similar observations were made in 
previous studies [12, 45]. This increase of specific IgA in 
BAL fluid from the vaccinated groups indicates an anam-
nestic immune response, and suggests that priming of 
the mucosal immune system is possible after parenteral 
vaccine administration. As T cells are required for iso-
type switching, it also confirms the priming of specific 
T helper cells by all three vaccines. Although the M. 
hyopneumoniae-specific IgA levels in BAL fluid are not 
completely in line with its levels in serum, it can however 
not be stated with certainty that all the detected antigen-
specific IgA in BAL fluid is produced locally. As with the 
M. hyopneumoniae-specific serum antibodies, the for-
mulation inducing the highest antigen-specific IgA levels 
after challenge infection did not offer the highest protec-
tion. This indicates that also other arms of the immune 
system play an important role in the protection against 
EP. It is also possible that mucosal IgA is only protective 
if induced pre-challenge. Clearly, developing an effective 
mucosal vaccine is required to address this question.
Two weeks after booster vaccination (D28), a signifi-
cantly higher percentage of M. hyopneumoniae-specific 
Th1 cells was observed in group SWE_TLR. Some ani-
mals in group Lipo_DDA:TDB also appeared to have such 
cells in the blood circulation. These results are in accord-
ance with the results from the study of Matthijs et  al. 
[21], where formulations Lipo_DDA:TDB and SWE_TLR 
induced a stronger M. hyopneumoniae-specific circulat-
ing Th1 response 2 weeks after booster vaccination. Only 
a few vaccinated animals had M. hyopneumoniae-specific 
circulating Th17 and  CD8+  TNF+IFN-γ+ T cells, while 
the study of Matthijs et al. [21] showed a significant Th17 
response in group PLGA_TLR and moderate to strong 
 CD8+ T cell responses in groups SWE_TLR and Lipo_
DDA:TDB, respectively. However, this lack of detect-
able M. hyopneumoniae-specific T cells should not be 
interpreted as a lack of T cell priming, as the frequency 
of antigen-specific T cells circulating in the periph-
eral blood compartment is a very dynamic process and 
changes over time. Following the expansion of specific 
T cells observed during a recall response (booster vacci-
nation or challenge for this experiment), the contraction 
phase corresponds to a huge decrease in the frequency 
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of antigen-specific T cells before they become memory 
cells. Even though memory cells are still circulating in the 
peripheral blood, their frequency is low as most memory 
cells recirculate between lymphoid tissue and blood, 
migrate to peripheral sites or the bone marrow for long-
term survival [46, 47]. It appears that in this study formu-
lation Lipo_DDA:TDB induced less circulating specific T 
cells compared to the study of Matthijs et al. [21], which 
might also be due to the fact that this vaccine was only 
applied IM in this study, while it was applied intrader-
mally and IM at primo-vaccination in the previous study. 
The change in administration route was necessary due 
to severe local reactions at the intradermal injection site 
[21]. Interestingly, the SWE_TLR formulation appeared 
the most capable of inducing cellular immunity detect-
able in the blood, and also offered the highest protection. 
Altogether, the data of this study support the hypothesis 
that cellular immunity is important for protection against 
EP.
Two weeks after challenge infection, group Lipo_
DDA:TDB had very high IL-1β levels compared to the 
other groups. This group also had the highest RDS at that 
time point. Several studies have associated the exces-
sive production of pro-inflammatory cytokines such as 
IL-1, IL-6 and TNF-α with the development of M. hyo-
pneumoniae-induced pneumonia [48–50]. According 
to Marchioro et  al. [36], vaccination might reduce lung 
damage by regulating the release of these pro-inflamma-
tory cytokines. However, in this study vaccination did not 
strongly impact the concentration of pro-inflammatory 
cytokines in the BAL fluid.
In conclusion, all formulations were able to reduce 
clinical symptoms, macro- and microscopic lung lesions 
and the M. hyopneumoniae DNA load in the lung, with 
the oil-in-water formulation delivering a cocktail of TLR-
ligands being the most effective. As the number of ani-
mals is limited in experimental infection studies, further 
research including more animals and raised under field 
conditions is needed to confirm the present results, and 
especially to assess the effects of the different vaccine 
formulations from this study on the reduction of per-
formance losses (ADG, FCR) due to M. hyopneumoniae 
infections.
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